ARTICLE | Distillery Therapeutics
Therapeutics: Fusobacterium nucleatum Fap2; T cell immunoreceptor with Ig and ITIM domains (TIGIT)
February 26, 2015 8:00 AM UTC
In vitro studies suggest inhibiting the interaction between F nucleatum Fap2 and human TIGIT could help improve the efficacy of immunotherapies to treat cancer. In co-cultures, F. nucleatum inhibited ...